JP2012024094A5 - - Google Patents

Download PDF

Info

Publication number
JP2012024094A5
JP2012024094A5 JP2011195901A JP2011195901A JP2012024094A5 JP 2012024094 A5 JP2012024094 A5 JP 2012024094A5 JP 2011195901 A JP2011195901 A JP 2011195901A JP 2011195901 A JP2011195901 A JP 2011195901A JP 2012024094 A5 JP2012024094 A5 JP 2012024094A5
Authority
JP
Japan
Prior art keywords
tau protein
tyrosine kinase
phosphorylation
sites
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011195901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012024094A (ja
JP5668201B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012024094A publication Critical patent/JP2012024094A/ja
Publication of JP2012024094A5 publication Critical patent/JP2012024094A5/ja
Application granted granted Critical
Publication of JP5668201B2 publication Critical patent/JP5668201B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011195901A 2004-06-21 2011-09-08 スクリーニング方法 Expired - Fee Related JP5668201B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58090104P 2004-06-21 2004-06-21
US60/580,901 2004-06-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007517457A Division JP5058792B2 (ja) 2004-06-21 2005-06-21 スクリーニング方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014150904A Division JP2014198054A (ja) 2004-06-21 2014-07-24 スクリーニング方法

Publications (3)

Publication Number Publication Date
JP2012024094A JP2012024094A (ja) 2012-02-09
JP2012024094A5 true JP2012024094A5 (enExample) 2012-11-29
JP5668201B2 JP5668201B2 (ja) 2015-02-12

Family

ID=35064772

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007517457A Expired - Fee Related JP5058792B2 (ja) 2004-06-21 2005-06-21 スクリーニング方法
JP2011195901A Expired - Fee Related JP5668201B2 (ja) 2004-06-21 2011-09-08 スクリーニング方法
JP2014150904A Pending JP2014198054A (ja) 2004-06-21 2014-07-24 スクリーニング方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007517457A Expired - Fee Related JP5058792B2 (ja) 2004-06-21 2005-06-21 スクリーニング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014150904A Pending JP2014198054A (ja) 2004-06-21 2014-07-24 スクリーニング方法

Country Status (8)

Country Link
US (3) US8367360B2 (enExample)
EP (2) EP1794313B1 (enExample)
JP (3) JP5058792B2 (enExample)
AU (1) AU2005253776B8 (enExample)
CA (1) CA2571614C (enExample)
DK (1) DK1794313T3 (enExample)
ES (1) ES2415665T3 (enExample)
WO (1) WO2005123048A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506302A (ja) * 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ａｂｌによるタウのリン酸化
ES2318616T3 (es) * 2006-06-01 2009-05-01 Cellzome Ag Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
WO2008009000A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2008057599A2 (en) * 2006-11-10 2008-05-15 Intra-Cellular Therapies, Inc. Methods for the treatment of abeta related disorders and compositions therefor
WO2008145789A1 (es) * 2007-05-28 2008-12-04 Pontificia Universidad Catolica De Chile Uso de compuestos derivados de benzamidina metanosulfonato o su sal farmacéuticamente aceptable, por ejemplo mesilato de imatinib, para preparar un medicamento para el tratamiento de la enfermedad neurodegenerativa de niemann pick de tipo c ( npc).
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
RU2595720C2 (ru) 2009-04-09 2016-08-27 Когнишн Терапьютикс, Инк. Ингибиторы снижения когнитивных способностей
US9192585B2 (en) 2009-07-31 2015-11-24 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2011044537A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. Methods for treating alzheimer's disease
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
RU2013140467A (ru) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Выделенные соединения из масла куркумы и способы применения
WO2013148283A1 (en) 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
KR101582852B1 (ko) * 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
JP2014147365A (ja) * 2013-02-04 2014-08-21 Osaka City Univ オリゴヌクレオチド構造体および遺伝子発現抑制方法
CN111254145A (zh) 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
TWI657819B (zh) * 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
JP6342627B2 (ja) * 2013-08-02 2018-06-13 国立大学法人 東京大学 筋萎縮性側索硬化症の新規病因遺伝子
AU2015210852B2 (en) 2014-01-31 2019-01-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
KR20160127825A (ko) * 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
US20180311236A1 (en) * 2015-10-28 2018-11-01 Ab Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
JP2017131191A (ja) * 2016-01-29 2017-08-03 国立大学法人京都大学 疾患の予防及び／又は治療剤のスクリーニング方法
ES2963428T3 (es) 2016-09-29 2024-03-27 Biogen Ma Inc Compuestos y métodos para reducir la expresión de Tau
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
WO2018216705A1 (ja) * 2017-05-23 2018-11-29 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
JP7197864B2 (ja) * 2017-05-31 2022-12-28 公立大学法人名古屋市立大学 アルツハイマー病バイオマーカー
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
BR112020018365A2 (pt) * 2018-03-13 2020-12-29 Janssen Pharmaceutica Nv Oligonucleotídeos modificados e métodos para uso em tauopatias
CN113272308B (zh) 2018-11-20 2025-03-18 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN110702665B (zh) * 2019-11-14 2022-03-22 济南大学 一种纸基耦合增强拉曼传感器制备及其在大田软海绵酸检测中的应用
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2024064729A1 (en) * 2022-09-20 2024-03-28 University Of Virginia Patent Foundation Syk activators and inhibitors in neurodegenerative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5514778A (en) * 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods

Similar Documents

Publication Publication Date Title
Bonfiglio et al. An HPF1/PARP1-based chemical biology strategy for exploring ADP-ribosylation
Erickson et al. Evaluating multiplexed quantitative phosphopeptide analysis on a hybrid quadrupole mass filter/linear ion trap/orbitrap mass spectrometer
Ficarro et al. Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment
Searle et al. Identification of protein modifications using MS/MS de novo sequencing and the OpenSea alignment algorithm
US11058903B2 (en) Methods for identifying and treating cachexia or pre-cachexia using an inhibitor of rage
JP2008504022A5 (enExample)
US7999080B2 (en) Reagents for the detection of protein phosphorylation in signaling pathways
Mayfield et al. Tyr1 phosphorylation promotes phosphorylation of Ser2 on the C-terminal domain of eukaryotic RNA polymerase II by P-TEFb
Parker et al. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition
Xue et al. Identification of extracellular signal-regulated kinase 1 (ERK1) direct substrates using stable isotope labeled kinase assay-linked phosphoproteomics
Tzouros et al. Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics
WO2008087035A3 (en) Screening method for anti-diabetic compounds
Nakayasu et al. A method to determine lysine acetylation stoichiometries
WO2005109001A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
Rai et al. Genome-wide analysis in Plasmodium falciparum reveals early and late phases of RNA polymerase II occupancy during the infectious cycle
Kaushik et al. The expression pattern of the phosphoproteome is significantly changed during the growth phases of recombinant CHO cell culture
JP2014503191A5 (enExample)
Zhou et al. Online Nanoflow RP− RP-MS Reveals Dynamics of Multicomponent Ku Complex in Response to DNA Damage
JP2015119721A5 (enExample)
Siibak et al. Antibiotic‐induced ribosomal assembly defects result from changes in the synthesis of ribosomal proteins
AU2016352895A1 (en) Methods of detecting and treating pulmonary hypertension
Gyenis et al. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2
Richter et al. Proteomic discovery of host kinase signaling in bacterial infections
Zoumaro-Djayoon et al. Targeted analysis of tyrosine phosphorylation by immuno-affinity enrichment of tyrosine phosphorylated peptides prior to mass spectrometric analysis
Mahadevan et al. TH2BS11ph histone mark is enriched in the unsynapsed axes of the XY body and predominantly associates with H3K4me3-containing genomic regions in mammalian spermatocytes